Ana Laura Pereira-Suárez

Dr. Ana Laura Pereira-Suárez


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2024 in Viruses
Verified
Journal Article
Open access
PDF file
CHChristian David Hernández-Silva
Christian David Hernández-Silva
JAJorge Adrian Ramirez de Arellano
Jorge Adrian Ramirez de Arellano
APAna Laura Pereira-Suárez
Ana Laura Pereira-Suárez
IRInocencia Guadalupe Ramírez-López
Inocencia Guadalupe Ramírez-López
Cervical cancer is primarily caused by Human Papillomavirus (HPV) infection and remains a significant public health concern, particularly in Latin American regions. This comprehensive narrative review addresses the relationship between Human Papillomavirus (HPV) and cervical cancer, focusing on Latin American women. It explores molecular and immunological aspects of HPV infection, its role in cervical cancer development, and the epidemiology in this region, highlighting the prevalence and diversity of HPV genotypes. The impact of vaccination initiatives on cervical cancer rates in Latin America is critically evaluated. The advent of HPV vaccines has presented a significant tool in combating the burden of this malignancy, with notable successes observed in various countries, the latter due to their impact on immune responses. The review synthesizes current knowledge, emphasizes the importance of continued research and strategies for cervical cancer prevention, and underscores the need for ongoing efforts in this field.

27 September 2024 in Cancers
Verified
Journal Article
Open access
PDF file
ARAbigail Gaxiola Rubio
Abigail Gaxiola Rubio
Luis Felipe Jave-SuárezLuis Felipe Jave-Suárez
Luis Felipe Jave-Suárez
CHChristian David Hernández-Silva
Christian David Hernández-Silva
JAJorge Adrian Ramirez de Arellano
Jorge Adrian Ramirez de Arellano
JVJulio César Villegas-Pineda
Julio César Villegas-Pineda
APAna Laura Pereira-Suárez
Ana Laura Pereira-Suárez
Background/Objectives: Estrogens and HPV are necessary for cervical cancer (CC) development. The levels of the G protein-coupled estrogen receptor (GPER) increase as CC progresses, and HPV oncoproteins promote GPER expression. The role of this receptor is controversial due to its anti- and pro-tumor effects. This study aimed to determine the effect of GPER activation, using its agonist G-1, on the transcriptome, cell migration, and invasion in SiHa cells and non-tumorigenic keratinocytes transduced with the HPV16 E6 or E7 oncogenes. Methods: Transcriptome analysis was performed to identify G-1-enriched pathways in SiHa cells. We evaluated cell migration, invasion, and the expression of associated proteins in SiHa, HaCaT-16E6, and HaCaT-16E7 cells using various assays. Results: Transcriptome analysis revealed pathways associated with proliferation/apoptosis (TNF-α signaling, UV radiation response, mitotic spindle formation, G2/M cell cycle, UPR, and IL-6/JAK/STAT), cellular metabolism (oxidative phosphorylation), and cell migration (angiogenesis, EMT, and TGF-α signaling) in SiHa cells. Key differentially expressed genes included PTGS2 (pro/antitumor), FOSL1, TNFRSF9, IL1B, DIO2, and PHLDA1 (antitumor), along with under-expressed genes with pro-tumor effects that may inhibit proliferation. Additionally, DKK1 overexpression suggested inhibition of cell migration. G-1 increased vimentin expression in SiHa cells and reduced it in HaCaT-16E6 and HaCaT-16E7 cells. However, G-1 did not affect α-SMA expression or cell migration in any of the cell lines but increased invasion in HaCaT-16E7 cells. Conclusions: GPER is a promising prognostic marker due to its ability to activate apoptosis and inhibit proliferation without promoting migration/invasion in CC cells. G-1 could potentially be a tool in the treatment of this neoplasia.

14 January 2026 in Cancers
Verified
Journal Article
Open access
PDF file
AIAna Karen Flores Islas
Ana Karen Flores Islas
Cecilia Rico FuentesCecilia Rico Fuentes
Cecilia Rico Fuentes
ESERICK SIERRA-DIAZ
ERICK SIERRA-DIAZ
MGMariel García-Chagollan
Mariel García-Chagollan
APAna Laura Pereira-Suárez
Ana Laura Pereira-Suárez
JAJorge Adrian Ramirez de Arellano
Jorge Adrian Ramirez de Arellano
Prostate cancer (PCa) is the leading cause of cancer-related deaths worldwide and the second most common cancer among men. Treatment options depend on factors like age, androgen sensitivity, PSA levels, Gleason score, TNM stage, and recurrence risk. Available treatments include hormonal therapy, radiation, surgery, and chemotherapy. Early immunological treatments were limited by poor lymphocyte infiltration and an immunosuppressive environment. Today, strategies such as dendritic cell vaccines, immune checkpoint inhibitors (ICIs), and adoptive cell therapy (ACT) are used. ACT, especially CAR T-cell strategies, aims to overcome traditional treatment limitations, particularly in advanced and metastatic castration-resistant prostate cancer (mCRPC), though it remains in early development. Personalized medicine uses molecular insights from the diseased tissue to tailor treatments. Variability in patient response, due to tumor heterogeneity and prior treatments, highlights the importance of personalized and combination therapies as future strategies for effective immunotherapy. This review explores the current landscape of PCa. We analyze treatment guidelines established by NCCN and EANM-ESTRO-ESUR-ISUP-SIOG. We comprehensively examine immunotherapeutic strategies currently available or under investigation for prostate cancer, with particular emphasis on ICIs, ACT with a focus on CAR T-cell therapy, combination approaches and therapeutic synergies, and predictive biomarkers of immunotherapy response. Additionally, we discuss the challenges and future directions in the implementation of immunotherapy for the management of prostate cancer.

14 May 2020 in Neurotoxicity Research
Verified
Journal Article
Closed access
PDF file
MGManuel de Jesús Gallegos-Saucedo
Manuel de Jesús Gallegos-Saucedo
GHGABRIELA CAMARGO HERNANDEZ
GABRIELA CAMARGO HERNANDEZ
ACAraceli Castillo-Romero
Araceli Castillo-Romero
MRMario A. Ramirez-Herrera
Mario A. Ramirez-Herrera
JBJacinto Bañuelos-Pineda
Jacinto Bañuelos-Pineda
LHLeonardo Hernandez-Hernandez
Leonardo Hernandez-Hernandez

Verified
Journal Article
Open access
PDF file
MAMaryam Nasiri Aghdam
Maryam Nasiri Aghdam
MGMariel Garcia-Chagollán
Mariel Garcia-Chagollán
APAna Laura Pereira-Suárez
Ana Laura Pereira-Suárez
Adriana Aguilar-LemarroyAdriana Aguilar-Lemarroy
Adriana Aguilar-Lemarroy
Luis Felipe Jave-SuárezLuis Felipe Jave-Suárez
Luis Felipe Jave-Suárez
Infection of epithelial cells with high-risk HPV (HR-HPV) types, followed by expression of virus oncogenic proteins (E5, E6, and E7), leads to genomic imbalance, suppression of tumor inhibitors, and induction of oncogenes. Low-risk HPV (LR-HPV) may slow the rate at which cervical cancer spreads to an invasive stage since co-infection with LR-HPV is linked to a decreased risk of future invasive cancer than infection with HR-HPV alone. We then propose that cancer-progressing changes may be distinguished through identifying the functional differences between LR-HPV and HR-HPV. Lentiviral strategies were followed to establish HaCaT cells with constitutive expression of HPV oncogenes. RNAseq experiments were designed to analyze the transcriptome modulations caused by each of the E5, E6, and E7 oncogenes of HPV-16 and HPV-84 in HaCaT cells. We identified enhanced RNA degradation, spliceosome, and RNA polymerase pathways related to mRNA processing. ATTS (alternative transcription termination site) was discovered to be more prevalent in cells with HPV-16E5 than HPV-84E5. In HPV-16E6-infected cells, ATTS gain was significantly higher than ATTS loss. Cells with HPV-16E7 had more isoforms with intron retention (IR) than those with HPV-84E7. We identified switches in ADAM10, CLSPN, and RNPS1 that led to greater expression of the coding isoforms in HR-HPV. The results of this work highlight differences between LR-HPV and HR-HPV in mRNA processing. Moreover, crucial cervical cancer-related switch events were detected.

12 August 2025 in Microbiology Research
Verified
Journal Article
Open access
PDF file
MDMariana Díaz-Zaragoza
Mariana Díaz-Zaragoza
Sergio Yair Rodríguez-PreciadoSergio Yair Rodríguez-Preciado
Sergio Yair Rodríguez-Preciado
LHLizeth Hernández-Ventura
Lizeth Hernández-Ventura
Alejandro Ortiz CovarrubiasAlejandro Ortiz Covarrubias
Alejandro Ortiz Covarrubias
GCGustavo Castellanos-García
Gustavo Castellanos-García
JMJose Macias-Barragan
Jose Macias-Barragan
Antibiotic resistance (AR) in environmental Escherichia coli represents a growing public health challenge. This study evaluated the prevalence of AR among E. coli isolates recovered from surface water bodies within the Ameca River basin in Jalisco, Mexico, and examined associations with anthropogenic influence and seasonal variation. Over a 1-year period, water samples were collected monthly from 16 sites, including tributaries, wetlands, and main river channels with differing degrees of urban impact. E. coli isolates were confirmed by malB gene PCR and tested for susceptibility to six antibiotics using the Kirby–Bauer disk diffusion method. High resistance frequencies were observed for ampicillin (93.9%), tetracycline (92.4%), and streptomycin (89.6%), while gentamicin exhibited the lowest resistance rate (48.1%). Resistance prevalence was significantly higher at sites adjacent to urban settlements and during the rainy season (p < 0.05). These findings underscore the influence of land use and seasonal dynamics on AR dissemination in aquatic environments and highlight the need for improved wastewater management strategies to mitigate the spread of resistant bacteria.